Amgen acquires BioVex Group Harris & Harris Group.

Amgen acquires BioVex Group Harris & Harris Group, Inc. notes that Amgen and BioVex Group, Inc., today announced the completion of the acquisition of BioVex Group, Inc. The transaction provides Amgen with BioVex’s lead product applicant, OncoVEXGM-CSF, a novel investigational oncolytic vaccine in Phase 3 clinical advancement that may represent a fresh method of treating melanoma and head and neck cancer. The acquisition was initially announced on January 24, 2011.The drugs used were the selective serotonin reuptake inhibitors nefazodone, venlafaxine and mirtazapine; all of the research were randomized and placebo-controlled. Related StoriesStudy shows link between exercise and depression in individuals at risk for heart diseaseAnxiety associated with poor asthma outcomesNegative body image significantly increases weight problems risk among adolescentsResearchers found that one in 100 participants in the research contained in the meta-analysis had new-onset suicidal ideation, or suicidal thoughts, while on medicine.